Form 4: International Stem Cell CORP Director Acquires Stock Options

Paul V. Maier, a director at International Stem Cell CORP, reports the acquisition of stock options.

Summary

• Paul V. Maier, a director of International Stem Cell CORP (ISCO.OB), filed a Form 4 with the SEC.
• The form details the acquisition of stock options to purchase shares of common stock.
• On June 11, 2024, Maier acquired options to buy 30,000 shares at $0.12, vesting on the earlier of June 11, 2025, or the date of the 2025 Annual Meeting of Stockholders.
• Additionally, Maier acquired options to buy 361,111 shares at $0.12, vesting in four equal quarterly increments starting September 11, 2024.
• Following these transactions, Maier directly owns options for 30,000 shares and 361,111 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It suggests confidence but doesn't provide concrete financial data.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules of the options suggest a long-term incentive structure for the director.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The granting of stock options could potentially align the director's interests more closely with those of the shareholders.

Key Dates

Keywords

Stock Options, Form 4, Director, Acquisition, ISCO.OB, International Stem Cell CORP, Beneficial Ownership